Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Read more:
Educational Resources: Access to webinars, Q&A sessions, and a wealth of information on nutrition, exercise, stress management, and sleep hygiene
Novo Nordisks oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
References 1 New England Journal of Medicine (2023)Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2 trial
Product Description Company Info
While retatrutide is being developed primarily as an obesity and diabetes treatment, the triple-agonist mechanism has implications beyond weight loss
US$ 24.88
US$ 26.67
US$ 28.65
US$ 25.44
